CRBP

+ Watchlist + Portfolio

Corbus Pharmaceuticals Holdings, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $9.99
52-Week Range: $7.12 – $20.56
Market Cap: $190.32M
P/E (TTM): —
EPS (TTM): -6.11
Dividend Yield: —

Advanced Metrics

Price/Book: 1.80
PEG Ratio: —
Return on Equity: -95.58%
Return on Assets: -53.00%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 5.71
Debt/Equity: 0.04
Total Debt: $4.26M
Free Cash Flow: $-49.62M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $79.54M

CRBP Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$16.14M	$31.17M	$32.22M	$70.09M
Selling, General & Admin	$18.70M	$13.91M	$16.50M	$15.21M
Operating Expenses	$34.84M	$45.08M	$48.72M	$85.31M
Operating Income	-$34.84M	-$45.08M	-$48.72M	-$85.31M
EBITDA	-$34.07M	-$40.10M	-$37.75M	-$78.30M
Pretax Income	-$42.35M	-$44.60M	-$40.21M	-$78.54M
Net Income	-$42.35M	-$44.60M	-$40.21M	-$78.54M
Diluted EPS	-10.15	-10.31	-3.68	-5.90
Diluted Shares	4.17M	4.33M	10.92M	13.32M

CRBP Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$17.00M	$13.72M	$17.20M	$28.49M
Current Assets	$60.18M	$23.55M	$152.98M	$166.95M
Total Assets	$66.31M	$28.27M	$155.88M	$168.19M
Current Liabilities	$12.64M	$31.89M	$11.82M	$20.69M
Long-Term Debt	$15.98M	—	—	—
Total Debt	$25.09M	$20.89M	$3.24M	$1.63M
Total Liabilities	$33.32M	$35.18M	$13.45M	$20.69M
Retained Earnings	-$392.08M	-$436.68M	-$476.89M	-$555.43M
Shareholders' Equity	$32.99M	-$6.91M	$142.43M	$147.50M
Working Capital	$47.54M	-$8.35M	$141.16M	$146.26M
Net Debt	$2.13M	$2.48M	—	—

CRBP Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$37.54M	-$36.10M	-$41.79M	-$64.49M
Capital Expenditure	-$13.45K	—	—	-$7.00K
Free Cash Flow	-$37.56M	-$36.10M	-$41.79M	-$64.50M
Depreciation & Amortisation	$763.00K	$641.00K	$588.00K	$233.00K
Stock-Based Compensation	$5.72M	$3.47M	$6.14M	$6.29M
Investing Cash Flow	$30.07M	$35.64M	-$121.31M	-$1.64M
Financing Cash Flow	-$533.62K	-$2.82M	$166.58M	$77.43M
Net Change in Cash	-$8.00M	-$3.28M	$3.47M	$11.29M

CRBP Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$15.64M	$15.19M	$20.86M	$18.41M	$19.82M
Selling, General & Admin	$4.13M	$3.96M	$3.56M	$3.56M	$4.49M
Operating Expenses	$19.77M	$19.15M	$24.42M	$21.97M	$24.30M
Operating Income	-$19.77M	-$19.15M	-$24.42M	-$21.97M	-$24.30M
EBITDA	-$19.69M	-$17.61M	-$23.29M	-$20.51M	-$24.25M
Pretax Income	-$16.98M	-$17.66M	-$23.34M	-$20.55M	-$22.97M
Net Income	-$16.98M	-$17.66M	-$23.34M	-$20.55M	-$22.97M
Diluted EPS	-1.39	-1.44	-1.90	-1.25	-1.23
Diluted Shares	12.20M	12.24M	12.31M	16.48M	18.71M

CRBP Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$18.90M	$20.04M	$26.98M	$28.49M	$25.66M
Current Assets	$137.36M	$122.83M	$107.57M	$166.95M	$143.57M
Total Assets	$139.93M	$125.08M	$109.51M	$168.19M	$144.48M
Current Liabilities	$11.62M	$13.33M	$17.06M	$20.69M	$18.14M
Total Debt	$2.85M	$2.46M	$2.05M	$1.63M	$1.21M
Total Liabilities	$12.82M	$14.09M	$17.37M	$20.69M	$18.14M
Retained Earnings	-$493.87M	-$511.53M	-$534.88M	-$555.43M	-$578.40M
Shareholders' Equity	$127.11M	$110.99M	$92.15M	$147.50M	$126.34M
Working Capital	$125.74M	$109.49M	$90.51M	$146.26M	$125.43M

CRBP Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$16.42M	-$16.60M	-$15.55M	-$15.92M	-$25.57M
Capital Expenditure	—	—	—	—	-$6.00K
Free Cash Flow	-$16.42M	-$16.60M	-$15.55M	-$15.93M	-$25.58M
Depreciation & Amortisation	$81.00K	$53.00K	$50.00K	$49.00K	$49.00K
Stock-Based Compensation	$1.71M	$1.56M	$1.58M	$1.43M	$1.92M
Investing Cash Flow	$18.12M	$17.74M	$19.64M	-$57.15M	$22.45M
Financing Cash Flow	$0.00	$0.00	$2.85M	$74.58M	—
Net Change in Cash	$1.70M	$1.14M	$6.94M	$1.51M	-$3.12M

Market Snapshot

About

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company headquartered in Norwood, Massachusetts, focused on developing precision medicines that target the endocannabinoid system. The company's pipeline includes drug candidates for the treatment of inflammatory and fibrotic diseases, including cystic fibrosis, systemic lupus erythematosus, and systemic sclerosis. Corbus leverages its understanding of cannabinoid receptor biology to develop novel therapeutics that modulate immune and inflammatory responses. The company is advancing multiple clinical programs aimed at addressing significant unmet medical needs in rare and serious diseases.